Sg3 Management, LLC Apellis Pharmaceuticals, Inc. Put Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $2.49 Million - $3.58 Million	-53,400 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $1.89 Million - $2.89 Million	53,400 New	53,400 $2.71 Million
Q4 2021 Feb 15, 2022	SELL	$30.74 - $49.16 $8.95 Million - $14.3 Million	-291,100 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $7.25 Million - $16.1 Million	231,000 Added 384.36%	291,100 $9.6 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $2.46 Million - $3.9 Million	60,100 New	60,100 $3.8 Million
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $461,850 - $858,000	-15,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$25.89 - $33.65 $388,350 - $504,750	15,000 New	15,000 $453,000

307

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.27B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.